Dimethyl itaconate inhibits antigen‐specific Th17 cell responses and autoimmune inflammation via modulating NRF2/STAT3 signaling

Abstract

AbstractPathogenic Th17 cells play a crucial role in autoimmune diseases like uveitis and its animal model, experimental autoimmune uveitis (EAU). Dimethyl itaconate (DMI) possesses potent anti‐inflammatory effects. However, there is still a lack of knowledge about the role of DMI in regulating pathogenic Th17 cells and EAU. Here, we reported that intraperitoneal administration of DMI significantly inhibited the severity of EAU via selectively suppressing Th17 cell responses. In vitro antigen stimulation studies revealed that DMI dramatically decreased the frequencies and function of antigen‐specific Th17, but not Th1, cells. Moreover, DMI hampered the differentiation of naive CD4+ T cells toward pathogenic Th17 cells. DMI‐treated DCs produced less IL‐1β, IL‐6, and IL‐23, and displayed an impaired ability to stimulate antigen‐specific Th17 activation. Mechanistically, DMI activated the NRF2/HO‐1 pathway and suppressed STAT3 signaling, which subsequently restrains p‐STAT3 nuclear translocation, leading to decreased pathogenic Th17 cell responses. Thus, we have identified an important role for DMI in regulating pathogenic Th17 cells, supporting DMI as a promising therapy in Th17 cell‐driven autoimmune diseases including uveitis.